CLINICAL_TRIALS
withdrawal
· 2016-11-08
Clinical Trial Update: Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Summary
A clinical trial evaluating Gallium-68 DOTATOC for the management of Neuroendocrine tumors is no longer available.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Northwell Health | Conditions: Neuroendocrine Tumors | Status: NO_LONGER_AVAILABLE